Atrial fibrillation (AFib) is a prevalent cardiac arrhythmia that significantly elevates the risk of stroke and systemic embolism. As a result, effective anticoagulation therapy is crucial for managing AFib patients. Over the past decade, novel oral anticoagulants (NOACs) have challenged traditional vitamin K antagonists, like warfarin, as preferred therapeutic options. Eliquis (apixaban) is one such […]